0FDB Stock Overview

A pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. More details

0FDB fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	4/6
Past Performance	1/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 78.5% below our estimate of its fair value

Earnings are forecast to grow 29.62% per year

Risk Analysis

Shares are highly illiquid

Does not have a meaningful market cap (NOK457M)

Large one-off items impacting financial results

Profit margins (3.7%) are lower than last year (6.1%)

My Notes

Capture your thoughts, links and company narrative

Navamedic ASA Competitors

ECO Animal Health Group

AIM:EAH

UK£48.1m

Animalcare Group

AIM:ANCR

UK£143.1m

Hikma Pharmaceuticals

LSE:HIK

UK£4.3b

C4X Discovery Holdings

AIM:C4XD

UK£30.3m

Price History & Performance

Summary of share price highs, lows and changes for Navamedic
Historical stock prices
Current Share Price	NOK 28.00
52 Week High	NOK 36.50
52 Week Low	NOK 24.90
Beta	0.45
1 Month Change	-8.79%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	348.00%

Recent updates

Shareholder Returns

	0FDB	GB Pharmaceuticals	GB Market
7D	12.0%	-1.7%	-2.6%
1Y	n/a	-3.5%	2.4%

Return vs Industry: Insufficient data to determine how 0FDB performed against the UK Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how 0FDB performed against the UK Market.

Price Volatility

Is 0FDB's price volatile compared to industry and market?
0FDB volatility
0FDB Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.1%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.6%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0FDB's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine 0FDB's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2002	45	Kathrine E. Andreassen	navamedic.com

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. The company’s product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet.

Navamedic ASA Fundamentals Summary

How do Navamedic's earnings and revenue compare to its market cap?
0FDB fundamental statistics
Market cap	NOK 457.47m
Earnings (TTM)	NOK 19.62m
Revenue (TTM)	NOK 525.55m

23.3x

P/E Ratio

0.9x

P/S Ratio

Is 0FDB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0FDB income statement (TTM)
Revenue	NOK 525.55m
Cost of Revenue	NOK 315.24m
Gross Profit	NOK 210.31m
Other Expenses	NOK 190.69m
Earnings	NOK 19.62m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 12, 2025

Earnings per share (EPS)	1.11
Gross Margin	40.02%
Net Profit Margin	3.73%
Debt/Equity Ratio	46.0%

How did 0FDB perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 16:03
End of Day Share Price	2024/12/16 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Navamedic ASA is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Espen Jørgensen	DNB Markets
Gediminas Ruginis	Norne Securities AS
Juste Subataviciute	Norne Securities AS